Black Friday for Spectrum as FDA lung cancer rejection prompts 75% cut to R&D workforce

Spectrum Pharmaceuticals is ending the year as it started it—with a round of layoffs. Friday’s announcement of a 75% reduction in its R&D workforce has been prompted by a complete response letter from the FDA that provided the final nail in the coffin for the biotech’s ambitions for its lung cancer candidate Pozenveo.